143 related articles for article (PubMed ID: 11068949)
1. Tumor hypoxia and anemia: impact on the efficacy of radiation therapy.
Kumar P
Semin Hematol; 2000 Oct; 37(4 Suppl 6):4-8. PubMed ID: 11068949
[TBL] [Abstract][Full Text] [Related]
2. Anemia, tumor hypoxemia, and the cancer patient.
Varlotto J; Stevenson MA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):25-36. PubMed ID: 16111569
[TBL] [Abstract][Full Text] [Related]
3. Impact of tumor hypoxia and anemia on radiation therapy outcomes.
Harrison LB; Chadha M; Hill RJ; Hu K; Shasha D
Oncologist; 2002; 7(6):492-508. PubMed ID: 12490737
[TBL] [Abstract][Full Text] [Related]
4. Impact of anemia in patients with head and neck cancer.
Kumar P
Oncologist; 2000; 5 Suppl 2():13-8. PubMed ID: 10896324
[TBL] [Abstract][Full Text] [Related]
5. The negative impact of anemia on radiotherapy and chemoradiation outcomes.
Shasha D
Semin Hematol; 2001 Jul; 38(3 Suppl 7):8-15. PubMed ID: 11523023
[TBL] [Abstract][Full Text] [Related]
6. Impact of Anemia in Patients With Head and Neck Cancer.
Kumar P
Oncologist; 2000 Jun; 5 Suppl 2():13-18. PubMed ID: 10889270
[TBL] [Abstract][Full Text] [Related]
7. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
Hoskin PJ; Robinson M; Slevin N; Morgan D; Harrington K; Gaffney C
J Clin Oncol; 2009 Dec; 27(34):5751-6. PubMed ID: 19884550
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment.
Harrison LB; Shasha D; Homel P
Oncology; 2002; 63 Suppl 2():11-8. PubMed ID: 12466640
[TBL] [Abstract][Full Text] [Related]
9. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
Prosnitz RG; Yao B; Farrell CL; Clough R; Brizel DM
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1087-95. PubMed ID: 15752888
[TBL] [Abstract][Full Text] [Related]
11. rHuEPO and treatment outcomes: the preclinical experience.
Ludwig H
Oncologist; 2004; 9 Suppl 5():48-54. PubMed ID: 15591422
[TBL] [Abstract][Full Text] [Related]
12. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
Overgaard J; Hoff CM; Hansen HS; Specht L; Overgaard M; Lassen P; Andersen E; Johansen J; Andersen LJ; Evensen JF; Alsner J; Grau C
Radiother Oncol; 2018 Apr; 127(1):12-19. PubMed ID: 29523409
[TBL] [Abstract][Full Text] [Related]
13. The use of epoetin alfa to increase and maintain hemoglobin levels during radiotherapy.
Dunst J
Semin Oncol; 2001 Apr; 28(2 Suppl 8):42-8. PubMed ID: 11395852
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck.
Shenouda G; Zhang Q; Ang KK; Machtay M; Parliament MB; Hershock D; Suntharalingam M; Lin A; Rotman M; Nabid A; Hong S; Shehata S; Cmelak AJ; Sultanem K; Le QT
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):907-15. PubMed ID: 25670542
[TBL] [Abstract][Full Text] [Related]
15. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.
Lee WR; Berkey B; Marcial V; Fu KK; Cooper JS; Vikram B; Coia LR; Rotman M; Ortiz H
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):1069-75. PubMed ID: 9869231
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of anemia in cancer patients undergoing radiation therapy.
Harrison L; Shasha D; Shiaova L; White C; Ramdeen B; Portenoy R
Semin Oncol; 2001 Apr; 28(2 Suppl 8):54-9. PubMed ID: 11395854
[TBL] [Abstract][Full Text] [Related]
17. Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer.
Janssens GO; Rademakers SE; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Takes RP; de Bree R; Hoogsteen IJ; Bussink J; Span PN; Kaanders JH
Clin Cancer Res; 2014 Mar; 20(5):1345-54. PubMed ID: 24452791
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
Cortesi E; Mancuso A; De Pasquale Ceratti A; Pizzardi N; D'Auria G; Accettura C; Beccaglia P; Bertelletti D; De Marinis F
Oncologist; 2004; 9(4):459-68. PubMed ID: 15266099
[TBL] [Abstract][Full Text] [Related]
19. Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale?
Baumann R; Depping R; Delaperriere M; Dunst J
Expert Rev Anticancer Ther; 2016 Jul; 16(7):751-8. PubMed ID: 27253509
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
